Business Wire·Jul 7, 2026, 10:00 AM ET

The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials

BAYRY BAYZF

Bayer has established its first academic medical center alliance for clinical trial collaboration with the University of Colorado Anschutz, UCHealth, & Children's Hospital Colorado.
The partnership aims to accelerate medical discovery, improve clinical trial efficiency, & expand patient access to investigational therapies.
Initial research focus areas include oncology, cardiovascular disease, chronic kidney disease, neurodegenerative disease, cell & gene therapy, women's health, & ophthalmology.
Key alliance objectives involve expanding clinical trial infrastructure to execute more studies faster, facilitating earlier patient access, & fostering collaboration between industry, academic researchers, clinicians, & health systems.
The collaboration combines Bayer's drug development expertise with the academic & clinical strengths of CU Anschutz, UCHealth, & Children's Colorado to expedite research.
Benefits include access to clinical & scientific experts for trial design, enhanced administrative & data science infrastructure to reduce launch times, & access to clinical data for identifying suitable patient populations.
A Phase III clinical trial site for an investigational cellular therapy for advanced Parkinson's disease has been selected at UCHealth University of Colorado Hospital.
Additional pediatric trial opportunities are being explored with physician-scientists at Children's Hospital Colorado to support its leading pediatric research program.
The alliance was formally introduced during a launch event at CU Anschutz, highlighting the shared commitment to improving human health through industry-academic partnerships.
In fiscal 2025, Bayer employed approximately 88,000 people with sales of 45.6 billion euros & R&D expenses of 5.8 billion euros.